Accenture plc (NYSE:ACN)
Accenture plc (NYSE:ACN) represented a move of 2.14 percent or $-2.75 per share and closed its previous day trading session at $164.52. 5.83 Million Shares were traded in the last trading session with an Average Volume of 2.2 Million Shares. The stock currently has a Market Capitalization of 102.82 Billion.
Accenture Plc is a management consulting, technology services and outsourcing organization. The Company’s business is structured around five operating groups, namely, Communications & High Tech, Financial Services, Products, Public Service and Resources. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. Accenture Plc is headquartered in New York.
The stock traded between $145.23 and $175.64 over 1-Year time period showing its price to sales ratio of 2.47. Accenture plc (NYSE:ACN) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $1.03 and 200-Day Simple Moving Average of $2.39. Its Price to Free Cash Flow is 27.52 and Price to Book of 10.17.
Analyst’s recommended the stock as 2.3 where 1 represents Strong Buy and 5 represents Sell.
In the last Quarter, Accenture plc (NYSE:ACN) reported its Actual EPS of $1.58/share. The analysts offering Earnings Estimates for the company were believing that Accenture plc could bring EPS of $1.56/share. The difference between Actual EPS and Estimated EPS was 0.02 Percent. Thus showing an Earnings Surprise of 1.3 Percent.
TESARO, Inc. (NASDAQ:TSRO)
In the last trading session, TESARO, Inc. (NASDAQ:TSRO) added its value by 1.33% closing at the price of $46.38. The stock currently has market capitalization of 2.52 Billion, with average volume of 2.3 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently TESARO, Inc. (NASDAQ:TSRO) is showing beta of 1.38. This particular value of beta suggests that TESARO, Inc. (NASDAQ:TSRO) has historically moved 138% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for TESARO, Inc. (NASDAQ:TSRO) is at $-11.91.
The stock currently has RSI of 67. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.
TESARO, Inc. (NASDAQ:TSRO) topped its 52-week high price of $87.93 on 12/04/17 and 52-Week Low Price of $23.41 on 11/09/18. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 9.16% and monthly volatility of 13.78% respectively.